Jericho, NY. Codagenix Inc., developers of a software-based platform for vaccine design, have secured $2M in Series A financing that the company will use to expand its vaccine to new targets, and for clinical testing of its ultra-low dose, live-attenuated Influenza vaccine. The investment was made by Topspin Fund of Roslyn, NY.
The financing follows the company’s seed funding over the past two years of $1.9M in NIH grants and an investment by Accelerate Long Island and the LIETF. With this latest round of investment capital, Codagenix will be taking the next step, looking to demonstrate safety and efficacy of a vaccine made using their platform in the clinic.
Nixon Peabody is Codagenix’s legal counsel. The deal team was led by Allan Cohen and Jason Chimon.